asa guidelines for glp-1 agonists How should we approach patients on agonists? Check out this excellent editorial from Dr. Girish Joshi, "Clarifying the and Decoding the Enigma: Strategies Anesthetic Management of Patients on Glucagon-Like Glucagon-Like Peptide-1 Agonists and General

By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future

Your genetics and medical history help determine which is better for you

Decision tree for use of GLP-1 receptor agonists indicated for weight control in patients with obesity or excess weight with comorbidities

Current law prohibits Medicare from covering obesity drugs and gives states flexibility to cover weight loss drugs under Medicaid Limitations on coverage for obesity drugs in Medicare and Medicaid mean that millions of people who have obesity and might benefit from taking GLP-1s may be unable to access them unless they are able to pay the full cash price out of their own pockets, which would likely be prohibitive for people with Medicaid who must have low incomes to qualify for the program, as well as for many people on Medicare with low and modest incomes

Hernandez et al., 2018